Women who get less than the recommended eight hours sleep a night are at higher risk of heart disease and heart-related problems than men with the same sleeping patterns. Research by the University of Warwick and University College London has found that levels of inflammatory markers vary significantly with sleep duration in women, but not men. The study, published today (Weds) in the American journal SLEEP, found levels of Interleukin-6 (IL-6), a marker related to coronary heart disease, were significantly lower in women who reported sleeping eight hours as compared with 7hours. A second marker, High-sensitivity C-reactive protein (hs-CRP), is predictive of future cardiovascular morbidity.
Mylan Inc. (NASDAQ: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This strength is in addition to Mylan's currently marketed 15 mg and 30 mg strengths of the product. Temazepam Capsules are the generic version of Mallinckrodt's Restoril® , a sleep aid, which had total U.S. sales of approximately $6 million for the 12 months ending March 31, according to IMS Health. Mylan has begun shipping this product. Currently, Mylan has 118 ANDAs pending FDA approval representing $82.
According to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, symptoms of Rheumatoid Arthritis (RA) negatively affect women's sleep. Sleep is further impaired by pain, depression and poor adherence to RA medications. Results indicate that length of time since RA diagnosis, RA disease activity, level of pain, depression symptoms and adherence to medications for RA may cause women suffering from the disease to have poor sleep quality. According to lead author Faith Luyster, PhD, of the University of Pittsburgh, Pa., findings emphasize the need for further research concerning poor RA medication adherence and sleep quality.
Stroke patients with obstructive sleep apnea (OSA) who undergo treatment with continuous positive airway pressure (CPAP) following their stroke may substantially reduce their risk of death, according to Spanish research to be published in the July 1 issue of the American Journal of Respiratory and Critical Care Medicine. "Our results suggest that patients with ischemic stroke and moderate to severe OSA showed an increased mortality risk, " wrote lead author, Miguel Angel MartĂ nez-GarcĂ a, M.D., of Requena General Hospital in Valencia, Spain. "CPAP treatment, although tolerated by only a small percentage of patients, is associated with a reduction in this excess risk and achieves a mortality [rate] similar to patients without OSA or with mild disease.
New imaging research in the June 24 issue of The Journal of Neuroscience helps explain why sleep deprivation affects some people more than others. After staying awake all night, those who are genetically vulnerable to sleep loss showed reduced brain activity, while those who are genetically resilient showed expanded brain activity, the study found. The findings help explain individual differences in the ability to compensate for lack of sleep. "The extent to which individuals are affected by sleep deprivation varies, with some crashing out and others holding up well after a night without sleep, " said Michael Chee, MBBS, at the Duke National University of Singapore Graduate Medical School, an expert on sleep deprivation who was not affiliated with the study.
Jazz Pharmaceuticals' (Nasdaq: JAZZ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase III data presented last week at the 2009 Associated Professional Sleep Societies meeting in Seattle, WA. These data have not been evaluated by the FDA or other regulatory authorities for use of sodium oxybate in the treatment of fibromyalgia. Widespread chronic pain is the hallmark of fibromyalgia, but the vast majority of patients are also affected by a broader constellation of symptoms, including fatigue, sleep disturbances, cognitive dysfunction, and impaired physical function.